Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle?

In The New England Journal of Medicine, Horn and colleagues have recently published the results of the IMPower133, a randomized, placebo-controlled, phase III trial, combining the programmed-death ligand 1 (PD-L1) inhibitor atezolizumab or placebo with carboplatin and etoposide in treatment-naive patients with extensive-stage small-cell lung cancer (SCLC) (1).